Houston, Texas 77079

  • Stage I


This clinical trial assesses whether a newly designed algorithm which looks at the genomic signature of each patient's tumor to predict their sensitivity to standard of care treatment verses being placed on a personally designed treatment trial can improve the responses in patients with newly diagnosed triple-negative breast cancer (TNBC). Testing the primary tumor biopsy for certain proteins and monitoring the lymphocyte infiltration into the tumors may help doctors determine the sub-type of TNBC, and direct treatments that may work well. It is not yet known whether assigning treatment based on the patient's tumor classification will improve how well the tumor responds.

Study summary:

PRIMARY OBJECTIVE: I. To conduct a prospective single arm, non-randomized trial to determine the impact of implementation of a research platform that includes diagnostic imaging to assess response to the initial phase of neoadjuvant chemotherapy combined with subtyping of TNBC in order to select the appropriate targeted therapy trial to complete neoadjuvant chemotherapy in patients found to have chemo-insensitive disease by imaging. SECONDARY OBJECTIVES: I. Measured as defined by Standardized Definitions for Efficacy End Points (STEEP) criteria using the following prioritization: distant recurrence free interval (DRFI), recurrence free survival (RFS), distant relapse-free survival (DRFS), overall survival (OS), invasive disease free survival (IDFS), disease free survival including ductal carcinoma in situ (DFS-DCIS). II. Evaluate the rates of enrollment into clinical trials for patients identified as having chemotherapy insensitive disease. III. Compare the rates of enrollment into therapeutic clinical trials between the two arms of the trial, i.e. those who do, versus do not, receive the results of molecular genomic prediction of chemotherapy response. IV. Evaluate the frequency of pathologic response rates (pCR, RCB I-III residual disease) in patients identified as chemotherapy sensitive versus insensitive. V. Compare the pathologic response rates of tumors between the two arms of the trial for the patients whose tumor was molecularly classified as chemotherapy- sensitive or chemotherapy-insensitive, and in whose neoadjuvant chemotherapy (NACT) followed the recommendation of the trial schema. VI. Determine the estimates of DRFI, RFS, DRFS, IDFS and DFS-DCIS at 3 years, and OS at 5 years in all patients. VII. Compare the estimates between the two arms of the trial for the patients whose tumor was molecularly classified as chemotherapy-sensitive or chemotherapy-insensitive, and for whose NACT followed the recommendation of the trial schema. VIII. Determine the pathologic response based on molecular characterization. IX. Determine the estimates of DRFI, RFS, DRFS, IDFS and DFS-DCIS at 3 years, and OS at 5 years. X. Subset analyses of pathologic response and 3-year DRFI, RFS, DRFS, IDFS and DFS-DCIS. XI. Estimate for the subsets where gene expression levels of receptor status (estrogen receptor [ER], progesterone receptor [PR] and HER2) were, or were not concordant with TNBC status as defined by routine diagnostic tests (immunohistochemistry and/or fluorescent in situ hybridization. XII. Compare the results of pathologic node-negative status (sentinel and/or non-sentinel nodes) after neoadjuvant chemotherapy according to a genomic predictor of nodal response to NACT, in subsets defined by pre-treatment clinical nodal status. EXPLORATORY OBJECTIVES: I. Future re-analysis of residual samples using a customized genomic diagnostic platform (integrated "prospective-retrospective" biomarker analysis) to predict chemotherapy sensitivity. II. Generation and subsequent molecular characterization of patient derived xenograph (PDX) models. III. Clinical diagnostic development studies using residual samples (fresh and/or formalin-fixed) within the Clinical Laboratory Improvement Amendments (CLIA)-compliant Molecular Diagnostics Laboratory and patient derived xenographs (PDX), to formally evaluate the clinical validity and utility of future clinical genomic diagnostic tests that would predict both response and survival from the treatments used in this clinical trial (correlative "retrospective-prospective" biomarker analyses). IV. Correlative science studies to identify molecular therapeutic targets for treatment-insensitive TNBC using residual samples and PDX models. V. Correlation of changes in diagnostic imaging to determine potential predictions of treatment responses. VI. Determine polymerase chain reaction (pCR) rates in a cohort of patients who undergo surgical resection after achieving complete radiological response after 4 cycles of adjuvant chemotherapy (AC). OUTLINE: Patients undergo baseline molecular and immunohistochemistry (IHC) evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 courses, and after 4 courses of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype. After completion of study treatment, patients are followed up for up to 5 years.


Inclusion Criteria: - The patient can undergo biopsy or surgery of a primary tumor site for suspected or proven invasive breast cancer of clinical stage I to III and are planned to receive neoadjuvant chemotherapy with anthracycline/taxane based regimes - The patient was proven to have TNBC, defined from standard pathologic assays as negative for ER and PR (< 10% tumor staining) and negative for HER2 (immunohistochemistry [IHC] score < 3, gene copy number not amplified) - Primary tumor sample was collected before NACT begins - Patients must have left ventricular ejection fraction (LVEF) > 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 12 weeks prior to starting adriamycin - Leukocytes > 3,000/mcL - Absolute neutrophil count > 1,500/mcL - Platelets > 100,000/mcL - Total bilirubin within normal institutional limits - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional upper limit of normal - Creatinine 1.5X the upper limits of normal OR creatinine clearance > 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal Exclusion Criteria: - The patient has diagnosis of stage IV disease or is found to have stage IV disease prior to start of NACT - Prior history of invasive cancer within 5 years of study entry or history of metastatic cancer; exceptions include non-metastatic, curatively treated basal and squamous cell carcinoma of the skin - Prior excisional biopsy of the primary invasive breast cancer - Patients with hematomas or biopsy site changes that limit response assessment of the primary tumor by diagnostic imaging - Patients not eligible for chemotherapy with taxane and/or anthracycline based chemotherapy regimens - Prior therapy with anthracyclines - Grade II or higher neuropathy - Patients with Zubrod performance status of > 2 - Patients with history of serious cardiac events defined as: - Patients with a history of New York Heart Association class 3 or 4 heart failure, or history of myocardial infarction, unstable angina or cerebrovascular accident (CVA) within 6 months of protocol registration - Patients who have history of PR prolongation (grade 2 or higher) or atrioventricular (AV) block



Primary Contact:

Principal Investigator
Stacy L Moulder
M.D. Anderson Cancer Center

Stacy Moulder
Phone: 713-792-2817
Email: smoulder@mdanderson.org

Backup Contact:


Location Contact:

Houston, Texas 77079
United States

Rachel L. Theriault
Email: rltheriault1@mdanderson.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.